Johnson & Johnson Updates Financials, FY23 Guidance Following Kenvue Separation, It Expects 2023 Reported Sales Growth of 7%-8% (Vs. Prior Range Of 6.5%–7.5%), Operational Growth Of 7.5%-8.5% (7%–8%), And Adjusted Operational Growth of 6.2%-7.2% (6%–7%)
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has updated its financials and FY23 guidance following the separation from Kenvue. The company now expects 2023 reported sales growth of 7%-8%, up from the previous range of 6.5%-7.5%. Operational growth is projected at 7.5%-8.5%, and adjusted operational growth at 6.2%-7.2%.
August 30, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's updated FY23 guidance following its separation from Kenvue indicates higher expected growth rates. This could potentially lead to a positive market reaction.
Johnson & Johnson's updated FY23 guidance shows increased growth expectations following its separation from Kenvue. This indicates a positive outlook for the company's performance, which could potentially lead to a positive market reaction and an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100